Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV

Mabel Toribio; Tricia H Burdo; Evelynne S Fulda; Madeline Cetlin; Sarah M Chu; Meghan N Feldpausch; Gregory K Robbins; Tomas G Neilan; Kathleen Melbourne; Steven K Grinspoon; Markella V Zanni

doi:10.1093/ofid/ofaa459

Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV

Open Forum Infect Dis. 2020 Sep 29;7(10):ofaa459. doi: 10.1093/ofid/ofaa459. eCollection 2020 Oct.

Affiliations

¹ Metabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Department of Neuroscience, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
³ Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
⁴ Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁵ Gilead Sciences, Inc., Foster City, California, USA.

Abstract

The NOD-like receptor protein family pyrin domain containing 3 (NLRP3) inflammasome, activated in the setting of HIV, contributes to pro-atherogenic inflammation. Among antriretroviral therapy-naïve people with HIV (vs controls), levels of caspase-1-a key component of the NLRP3 inflammasome-were significantly increased. Six months of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate significantly decreased caspase-1 levels in association with CD4+/CD8+ ratio recovery.

Trial registration. ClinicalTrials.gov NCT01766726.

Keywords: HIV; NLRP3 inflammasome; atherosclerosis; cardiovascular disease; caspase-1; pyroptosis.

Associated data

ClinicalTrials.gov/NCT01766726

Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV

Authors

Affiliations

Abstract

Associated data

Grants and funding